George Prendergast, PhD, Lankenau Institute for Medical Research (LIMR), Wynnewood, PA, discusses the preclinical modeling of the SYNC-T solid tumor therapy platform, which utilizes cryo-immune vaccination. Freezing portions of the tumor can release antigens, making tumors more amenable to immunotherapies. Preclinical animal models have demonstrated the potential of this approach and has shown to be less toxic than systemic therapies. This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.